Melanotan-1

What is Melanotan-1?

In plain words: Melanotan-1 is a lab-made hormone that tells skin cells to produce more dark pigment. Technically speaking, Melanotan-1 (afamelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone that selectively activates melanocortin-1 receptors to increase skin pigmentation. It is crucial to distinguish it from Melanotan-II, a different peptide with additional sexual and metabolic effects, as Melanotan-1 is specifically approved as a medical implant for light intolerance.

Afamelanotide is a linear peptide consisting of 13 amino acids, making it highly selective for the MC1R. In contrast, Melanotan-II is a cyclic 7-amino-acid peptide that non-selectively binds to other receptors like MC3R and MC4R, causing side effects such as spontaneous erections. Because of these differing profiles, the clinical data of one peptide cannot be applied to the other. As the prescription drug Scenesse, Melanotan-1 is approved by the EMA and FDA, but strictly for erythropoietic protoporphyria (EPP) and never as a cosmetic tanning product.

How does Melanotan-1 work?

Melanotan-1 works by highly selectively binding as an agonist to the melanocortin-1 receptor (MC1R) on epidermal melanocytes, which activates a cAMP cascade (in simple terms: an internal cell signalling chain that passes the command "make more pigment" along the cell) that switches on the production of dark eumelanin while reducing the formation of aggressive free radicals.

By stabilizing the pigment-producing pathway, Melanotan-1 triggers melanocytes to synthesize eumelanin (dark pigment) instead of phaeomelanin (light pigment). Eumelanin acts as a biological, wavelength-neutral filter. It absorbs and scatters ultraviolet light while scavenging free radicals, providing a built-in photoprotective layer. Because Melanotan-1 is a linear structure that resists immediate enzymatic degradation, its pigment-stimulating effects last significantly longer than those of the body's natural hormones.

How effective is Melanotan-1?

Melanotan-1 is highly effective at inducing pigmentation and photoprotection, with a landmark 1991 human study demonstrating significant tanning without any UV light exposure, while subsequent cell models showed comparable pigmentation requiring 50 % less UV light and resulting in 47 % fewer sunburn cells.

A primary reason individuals investigate this peptide is the claim that it tans without sunlight. This is scientifically supported: the first human study by Levine et al. in 1991 involved 28 healthy men who received daily subcutaneous injections over 10 days. The results showed significant, dose-dependent tanning without any UV exposure. However, researchers emphasize that photoprotection implies an enhancement of the body's natural defenses, not a replacement for regular sunscreen or physical sun protection measures.

The Afamelanotide clinical program

The Afamelanotide clinical program primarily revolves around its approval for erythropoietic protoporphyria (EPP), but research also extends to preventing skin cancer in organ transplant recipients and treating vitiligo, demonstrating its potential as a serious medical photoprotectant rather than a cosmetic agent.

Following successful pivotal Phase 3 trials that led to its regulatory approval for EPP, researchers expanded the clinical applications of Afamelanotide. It has been investigated as a promising photoprotective treatment for organ transplant recipients, who are highly susceptible to actinic keratoses and squamous cell carcinomas. Furthermore, a proof-of-concept study (NCT01430195) evaluated the combination of Afamelanotide implants with narrowband UVB light for treating non-segmental vitiligo, though it currently lacks approval for these additional conditions.

Dosage: what studies show - and the protocol

The only officially validated dosage is a 16 mg subcutaneous implant administered every two months prior to and during high-sunlight periods, with a maximum of three to four implants per year, while no approved dosing exists for any injectable formulation.

The approved medical protocol dictates that the bioresorbable Scenesse implant must be inserted subcutaneously by specialized physicians in accredited porphyria centers. This strict medical oversight ensures patient safety and precise dosing. For illicit injectable powders sold on the unregulated market, no standardized human dosing protocols exist, making any self-calculated dosing highly experimental and risky.

Handling & Storage

In its approved medical form, Melanotan-1 is handled strictly as a solid 16 mg bioresorbable implant inserted subcutaneously by professionals, whereas unregulated black-market powders requiring liquid reconstitution pose significant unknown risks regarding sterility, correct mixing procedures, and the actual peptide content.

The approved Scenesse implant does not require mixing or cold storage by the end-user, as it is dispensed and administered entirely within a clinical setting. Conversely, illicit products typically arrive as lyophilized (freeze-dried) powders. Handling these unregulated substances requires mixing them with bacteriostatic water, a process highly prone to contamination and dangerous dosing errors if not performed in a sterile laboratory environment.

Side effects and common mistakes

The most common side effects include nausea, headaches, flushing, and appetite loss, while a critical risk involves the darkening of existing moles and the appearance of new ones, which can severely mask early signs of melanoma during skin cancer screenings.

Unregulated application carries severe health risks. Skin changes such as uneven darkening and longitudinal melanonychia (dark stripes on the nails) are frequently reported. Because these pigment changes can obscure the standard ABCDE warning signs of skin cancer (Asymmetry, Border, Color, Diameter, Evolution), early melanoma detection becomes exceptionally difficult for dermatologists. Furthermore, black-market products are often mislabeled or contaminated, sometimes containing the riskier Melanotan-II, which introduces dangers like renal dysfunction and prolonged erections (priapism).

• Confusing MT-1 with MT-II: Assuming the data and safety profiles are identical, leading to unexpected sexual or metabolic side effects from MT-II.
• Skipping sunscreen: Believing that photoprotection provides complete immunity, thereby increasing severe UV-induced skin damage risks.
• Ignoring mole changes: Failing to have rapidly darkening or new moles evaluated by a doctor due to assumed peptide-induced hyperpigmentation.
• Unsafe reconstitution: Mixing unregulated black-market powders without sterile equipment, leading to severe bacterial infections.

Approval and legal status

Melanotan-1 (afamelanotide) is legally approved in the EU (since 2014) and the USA (since 2019) exclusively as the Scenesse implant for adults with erythropoietic protoporphyria, holding Orphan Drug status, while all unregulated cosmetic tanning products containing melanotan remain unauthorized and illegal.

Health authorities globally strictly warn against internet-purchased Melanotan products. Agencies such as Australia's TGA and various medical societies describe these unregulated tanning products as "far from safe," noting that purchasing and using them without a prescription is illegal in many jurisdictions. The strict medical limitation to a prescription-only implant for a rare disease underscores the clear boundary between supervised clinical photoprotection and hazardous cosmetic use.